UNASSIGNED: Studies published until March 2024 were reviewed, encompassing randomized clinical trials (RCTs) without temporal or linguistic constraints, comparing WBV exercise with other interventions. The PubMed/MEDLINE, Scopus, Cochrane Airways Trials Register, and CINAHL databases were queried. The Revised Cochrane risk-of-bias tool for randomized trials 2.0A was employed for quality assessment.
UNASSIGNED: Among 351 screened studies, 7 met the criteria, totaling 356 participants (WBV group, n = 182; control group, n = 174). Meta-analysis revealed a significant mean difference of 41.36 m [95%CI (13.28-69.44); p = .004] in the 6-minute walk test distance favoring the WBV group for functional capacity. Lower limb muscle strength improved in 57.14% of included studies. HRQoL meta-analysis demonstrated a 1.13-point difference [95%CI -1.24-3.51; p = .35] favoring WBV, although group differences were not significant. A mean difference of 2.31 points favored the control group in health condition [95%CI (-1.32-5.94); p = .021].
UNASSIGNED: WBV exercise is recognized as a promising therapeutic modality for severe COPD patients, notably enhancing functional capacity. Although heterogeneous study protocols weaken the evidence for clinically relevant outcomes, improvements in lower limb muscle strength and HRQoL were also observed, differences between groups were not significant.
■对2024年3月之前发表的研究进行了回顾,包括没有时间或语言限制的随机临床试验(RCT),将WBV锻炼与其他干预措施进行比较。PubMed/MEDLINE,Scopus,Cochrane航空公司试验登记簿,和CINAHL数据库进行了查询。采用经修订的Cochrane随机对照试验偏倚风险工具2.0A进行质量评估。
■在351项筛选研究中,7符合标准,共356名参与者(WBV组,n=182;对照组,n=174)。荟萃分析显示,6分钟步行测试距离的平均差异为41.36m[95CI(13.28-69.44);p=.004],有利于WBV组的功能能力。纳入研究的57.14%患者下肢肌力得到改善。HRQoL荟萃分析显示1.13点差异[95CI-1.24-3.51;p=.35]有利于WBV,虽然组间差异不显著。在健康状况下,平均2.31点的差异有利于对照组[95CI(-1.32-5.94);p=.021]。
■WBV运动被认为是严重COPD患者的一种有希望的治疗方式,显著增强功能能力。尽管异质性研究方案削弱了临床相关结果的证据,还观察到下肢肌肉力量和HRQoL的改善,组间差异不显著.